好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

18F-AV-1451 Tau Tracer Uptake Correlates with Medial Temporal Lobe Subregional Atrophy in Amyloid Negative Individuals
Aging and Dementia
P6 - Poster Session 6 (11:30 AM-1:00 PM)
9-001

While the hippocampal cornu ammonis 1 (CA1) subfield is known to be an early site of tau pathology in Alzheimer’s disease (AD), it is unclear how tau pathology in Primary Age Related Tauopathy (PART), defined by the presence of tau-based neurofibrillary tangles in the absence of beta amyloid, relates to subfield structure.

 

To investigate  relationships between the amount of tau binding measured by AV1451 PET imaging and atrophy within medial temporal lobe (MTL) subregions, as measured by MTL-focused high-resolution structural MRI in individuals classified as either Amyloid-β positive or negative based on Florbetapir-PET imaging.

We studied 188 participants from ADNI across the spectrum of disease stages (114 Amyloid- , 73 Amyloid+). High-resolution T2-MRI was used for making MTL subregional atrophy measurements. ASHS segmentation software produced volumetric measurements of hippocampal subfields and  parahippocampal (PHC), entorhinal (ERC), and perirhinal (PRC) cortices. Regional thickness maps were generated within the MTL cortical ribbon. A summary measure of MTL tau tracer uptake was obtained from 18F-florbetapir Tau-PET scans. Tracer uptake was correlated with atrophy measures. Intracranial volume, age, and time between MRI and PET scans were used as covariates.

 

Both ROI and regional thickness analysis revealed strong relationships between atrophy measures and tau tracer uptake. Correlations were strongest within the BA35 region of PRC, approximating transentorhinal cortex, and ERC in both Amyloid- and Amyloid+ subsets. Within the CA fields, regional thickness analysis revealed greater correlation more medially, near CA2 subfield, in Amyloid- , in contrast with CA1 subfield in Amyloid+.

These results represent the first in-vivo evidence of subregion-specific correlations between tau burden and local atrophy in both Amyloid+ and Amyloid- individuals. Strongest effects in BA35, followed by ERC, and CA1 subfield mirror the progression of tau pathology along Braak stages. Stronger  effect near CA2 in Amyloid- supports recent pathological evidence of CA2 tau accummulation in PART.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
David A. Wolk, MD, FAAN (University of Pennsylvania) Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Functional Neuromodulation. Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. The institution of Dr. Wolk has received research support from Biogen. Dr. Wolk has received publishing royalties from a publication relating to health care. Dr. Wolk has received personal compensation in the range of $5,000-$9,999 for serving as a CME speaker with Eli Lilly.